Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.
about
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effectsBiochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseThe endocannabinoid system as an emerging target of pharmacotherapyInactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoidsMechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymesChemical probes of endocannabinoid metabolismThe pharmacological landscape and therapeutic potential of serine hydrolasesStructure-guided inhibitor design for human FAAH by interspecies active site conversionDiscovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory PainBinding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal StructuresX-ray Crystallographic Analysis of α-Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide HydrolaseCrystal Structure of Fatty Acid Amide Hydrolase Bound to the Carbamate Inhibitor URB597: Discovery of a Deacylating Water Molecule and Insight into Enzyme InactivationFluoride-Mediated Capture of a Noncovalent Bound State of a Reversible Covalent Enzyme Inhibitor: X-ray Crystallographic Analysis of an Exceptionally Potent α-Ketoheterocycle Inhibitor of Fatty Acid Amide HydrolaseReversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting AnalgesicsDiscovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)A Binding Site for Nonsteroidal Anti-inflammatory Drugs in Fatty Acid Amide HydrolaseRational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site ResiduesFAAH inhibitors in the limelight, but regrettablyDual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain ManagementInhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future AntidepressantsFatty acid amide hydrolase inhibitors: a patent review (2009-2014)Preclinical Characterization of the FAAH Inhibitor JNJ-42165279Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addictionFatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disordersLatest advances in the discovery of fatty acid amide hydrolase inhibitorsElevating endocannabinoid levels: pharmacological strategies and potential therapeutic applicationsEnzymatic pathways that regulate endocannabinoid signaling in the nervous systemAnti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury modelPotential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of AnxietyChronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.A chemical genetic screen uncovers a small molecule enhancer of the N-acylethanolamine degrading enzyme, fatty acid amide hydrolase, in ArabidopsisLong-term consequences of perinatal fatty acid amino hydrolase inhibition.Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityInteractions of Cannabinoids With Biochemical SubstratesFAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administrationStrategies for discovering and derisking covalent, irreversible enzyme inhibitors.The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
P2860
Q24569799-B8E150D0-7E4F-448A-AC97-43BF3FE6D634Q24620186-A62DD0CD-8DBD-49D9-BCA4-04266F576BE6Q24648473-B408E628-6924-49A6-8EA3-86FB155A9ACCQ24680497-62E4A59A-3945-42C6-94BE-F9A461A4D0C6Q24680869-28D7ADCB-E589-4A21-B5FA-FE15D2DCD329Q26863202-39DE3374-31C9-4874-AF04-C23F0ACCD507Q26995817-2C9F3BFE-1527-42A7-B702-22F780A5A4EFQ27651822-1DD5D031-D1DB-48F1-A9EC-34984E0C2CDDQ27655121-BC7E6454-1F19-4CDF-B926-6E4E5A540E34Q27657268-D3EEB702-3348-4C2B-8046-4B4AC67D6733Q27658264-B2BDCFFD-906A-4EEC-8526-6D12C9927A6FQ27661834-8085B5D7-FE30-4FFD-979B-EB7192BB5BF2Q27667078-F08017FE-2C2B-4932-8FBB-A29B8D055556Q27667312-AC3A0CBD-12B1-4088-BF0D-D3D467481B0CQ27667550-05BFA3B6-6331-42F2-9B46-26D5A48A2A04Q27675504-A8B46B1C-E898-4E03-9173-FBC564D87A4FQ27677344-DDE620FE-DE23-4F3F-9A68-65AEE5931D4EQ28067151-57ACCA46-4F4D-45C9-863D-7579CDEB538FQ28067493-23BDEABD-15D2-4F6E-9807-187D345DCCD5Q28082891-3FF8EA16-1185-40BF-979F-7FB22EE7AE8BQ28267884-1EC3E2B5-E0A4-47D5-B093-2A1D7723FBBCQ28271553-6197B228-A4D2-4430-8687-DA2DC9B62D95Q28283718-E8CD4805-5A6B-4721-AF14-1207EB8C4D40Q28285103-0C2CD426-50D1-444E-9E96-7E53C00BC221Q28287173-7393211D-4E69-4DA0-A74E-4B246D12B64BQ28300390-18F2A312-6B0C-4B61-971E-96029FC20CEAQ28390932-BDC13CED-EA4B-4518-A98C-1002F6B79366Q28485098-37DFAE45-440A-4768-91F8-F20A7894312EQ28547916-083BFD7F-52DD-4610-9E7D-2227AA8799B7Q28590486-E60329B1-4586-442F-805C-B49F8FE3870DQ28818594-8CE70FC8-F6E2-445B-A102-E572F46AC2B3Q30417555-731F724E-8A47-4169-8C6A-472F0DFC2244Q30492114-933EF30E-4EB6-45ED-BD8A-6238DE875ADCQ33644120-D7FF622B-DD4F-4545-A35D-0974D38A2214Q33714587-186CCFD5-A3D9-49A9-82B8-51645E8A23FDQ33751118-637C9315-95DF-4642-9AC1-1445B4558F13Q33758351-F02EB647-62D8-41AC-9664-25DF608F7292Q33956795-0D280003-C224-4937-9C23-8A7981D01DD8Q34023143-A8DFE6D7-E2B8-49CD-8E8A-745E49F3B393Q34027721-F1D13DD1-CBFF-4E2E-92FB-6A3927E74304
P2860
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Reversible inhibitors of fatty ...... on of potency and selectivity.
@en
Reversible inhibitors of fatty ...... on of potency and selectivity.
@nl
type
label
Reversible inhibitors of fatty ...... on of potency and selectivity.
@en
Reversible inhibitors of fatty ...... on of potency and selectivity.
@nl
prefLabel
Reversible inhibitors of fatty ...... on of potency and selectivity.
@en
Reversible inhibitors of fatty ...... on of potency and selectivity.
@nl
P2093
P356
P1476
Reversible inhibitors of fatty ...... on of potency and selectivity.
@en
P2093
Alan Saghatelian
Aron H Lichtman
Christophe Hardouin
Christopher C Shelton
Dale L Boger
Donmienne Leung
P304
P356
10.1124/JPET.104.069401
P407
P577
2004-06-30T00:00:00Z